Abstract
Indatuximab ravtansine (BT062) was investigated in patients with relapsed and/or refractory multiple myeloma. Indatuximab ravtansine was generally well-tolerated and showed anti-tumor activity. Based on the study results, a multi-dose schedule was selected for further clinical investigation in combination regimens.
Original language | English (US) |
---|---|
Journal | Clinical Lymphoma, Myeloma and Leukemia |
DOIs | |
State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Antibody-drug conjugate
- CD138
- Monoclonal antibody
- Multiple-dose
- Syndecan-1
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. / Jagannath, Sundar; Heffner, Leonard T.; Ailawadhi, Sikander; Munshi, Nikhil C.; Zimmerman, Todd M.; Rosenblatt, Jacalyn; Lonial, Sagar; Chanan Khan, Asher A; Ruehle, Markus; Rharbaoui, Faiza; Haeder, Thomas; Wartenberg-Demand, Andrea; Anderson, Kenneth C.
In: Clinical Lymphoma, Myeloma and Leukemia, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
AU - Jagannath, Sundar
AU - Heffner, Leonard T.
AU - Ailawadhi, Sikander
AU - Munshi, Nikhil C.
AU - Zimmerman, Todd M.
AU - Rosenblatt, Jacalyn
AU - Lonial, Sagar
AU - Chanan Khan, Asher A
AU - Ruehle, Markus
AU - Rharbaoui, Faiza
AU - Haeder, Thomas
AU - Wartenberg-Demand, Andrea
AU - Anderson, Kenneth C.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Indatuximab ravtansine (BT062) was investigated in patients with relapsed and/or refractory multiple myeloma. Indatuximab ravtansine was generally well-tolerated and showed anti-tumor activity. Based on the study results, a multi-dose schedule was selected for further clinical investigation in combination regimens.
AB - Indatuximab ravtansine (BT062) was investigated in patients with relapsed and/or refractory multiple myeloma. Indatuximab ravtansine was generally well-tolerated and showed anti-tumor activity. Based on the study results, a multi-dose schedule was selected for further clinical investigation in combination regimens.
KW - Antibody-drug conjugate
KW - CD138
KW - Monoclonal antibody
KW - Multiple-dose
KW - Syndecan-1
UR - http://www.scopus.com/inward/record.url?scp=85063451981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063451981&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2019.02.006
DO - 10.1016/j.clml.2019.02.006
M3 - Article
C2 - 30930134
AN - SCOPUS:85063451981
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2669
ER -